NEW YORK (Reuters Health) – An individualized risk communication tool, Predict Prostate, leads to more realistic perceptions about survival, thereby facilitating treatment decisions for newly diagnosed...

A novel radiopharmaceutical has been shown to boost survival when added to standard treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease had progressed after...

It was a cloudy October morning, and Joseph E. Oesterling, MD, was in the exam room of his Saginaw, Michigan urology practice preparing for a procedure. Suddenly, the door burst open, and a federal agent...

NEW YORK (Reuters Health) – The Decipher genomic classifier (GC) is a promising tool to help determine which men will benefit from hormone therapy in addition to salvage radiation after radical prostatectomy,...

The genomic landscape of circulating tumor DNA (ctDNA) was comparable to the landscape of tissue biopsies in a large study of patients with metastatic castration-resistant prostate cancer (mCRPC), according...